{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:34:49Z","timestamp":1709685289736},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s00120-006-1059-x","type":"journal-article","created":{"date-parts":[[2006,5,4]],"date-time":"2006-05-04T01:05:04Z","timestamp":1146704704000},"page":"629-636","source":"Crossref","is-referenced-by-count":7,"title":["Wirkmechanismen der intravesikalen BCG-Immuntherapie des oberfl\u00e4chlichen Harnblasenkarzinoms","Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer"],"prefix":"10.1007","volume":"45","author":[{"given":"A.","family":"B\u00f6hle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Suttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brandau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1059_CR1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","volume":"27","author":"Arnold","year":"2004","unstructured":"Arnold J, de Boer EC, O\u2019Donnell MA et al. (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 27: 116\u2013123","journal-title":"J Immunother"},{"key":"1059_CR2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"Behr","year":"1999","unstructured":"Behr MA, Wilson MA, Gill WP et al. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520\u20131523","journal-title":"Science"},{"key":"1059_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","volume":"144","author":"B","year":"1990","unstructured":"B\u00f6hle A, Gerdes J, Ulmer AJ et al. (1990) Effects of local bacillus Calmette-Gu\u00e9rin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53\u201358","journal-title":"J Urol"},{"key":"1059_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","volume":"144","author":"B","year":"1990","unstructured":"B\u00f6hle A, Busemann E, Gerdes J et al. (1990) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Gu\u00e9rin immunotherapy. J Urol 144: 59\u201364","journal-title":"J Urol"},{"key":"1059_CR5","first-page":"3729","volume":"6","author":"Brandau","year":"2000","unstructured":"Brandau S, Suttmann H, Riemensberger J et al. (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6: 3729\u20133738","journal-title":"Clin Cancer Res"},{"key":"1059_CR6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","volume":"92","author":"Brandau","year":"2001","unstructured":"Brandau S, Riemensberger J, B\u00f6hle A et al. (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697\u2013702","journal-title":"Int J Cancer"},{"key":"1059_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","volume":"39","author":"Brandau","year":"2001","unstructured":"Brandau S, Bohle A (2001) Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol 39: 518\u2013524","journal-title":"Eur Urol"},{"key":"1059_CR8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0952-7915(93)90128-F","volume":"5","author":"Chapman","year":"1993","unstructured":"Chapman PB, Houghton AN (1993) Non-antibody immunotherapy of cancer. Curr Opin Immunol 5: 726\u2013731","journal-title":"Curr Opin Immunol"},{"key":"1059_CR9","first-page":"465","volume":"165","author":"ChenX","year":"2001","unstructured":"ChenX, LuoY, YamadaH, O\u2019Donnell MA (2001) BCG potentiates human chemokine induction in vivo and in vitro. J Urol A 165: 465","journal-title":"J Urol A"},{"key":"1059_CR10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-5347(01)65748-3","volume":"156","author":"Chin","year":"1996","unstructured":"Chin JL, Kadhim SA, Batislam E et al. (1996) Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156: 1189\u20131193","journal-title":"J Urol"},{"key":"1059_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0094-0143(05)70242-1","volume":"27","author":"Clinton","year":"2000","unstructured":"Clinton SK, Canto E, O\u2019Donnell MA (2000) Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 27: 147\u2013155","journal-title":"Urol Clin North Am"},{"key":"1059_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","volume":"19","author":"de","year":"1991","unstructured":"de\u00a0Boer EC, de\u00a0Jong WH, van der Meijden AP et al. (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19: 45\u201350","journal-title":"Urol Res"},{"key":"1059_CR13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","volume":"34","author":"de","year":"1992","unstructured":"de\u00a0Boer EC (1992) Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer. Cancer Immunol Immunother 34: 306\u2013312","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00941903","volume":"25","author":"de","year":"1997","unstructured":"de\u00a0Boer EC (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25: 31\u201334","journal-title":"Urol Res"},{"key":"1059_CR15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00296835","volume":"21","author":"de","year":"1993","unstructured":"de\u00a0Reijke TM Vos PCN, de\u00a0Boer EC et al. (1993) Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmette-Gu\u00e9rin. Urol Res 21: 349\u2013352","journal-title":"Urol Res"},{"key":"1059_CR16","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","volume":"154","author":"Esuvaranathan","year":"1995","unstructured":"Esuvaranathan K (1995) Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154: 572\u2013575","journal-title":"J Urol"},{"key":"1059_CR17","first-page":"2834","volume":"59","author":"Gunther","year":"1999","unstructured":"Gunther JH, Jurczok A, Wulf T et al. (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59: 2834\u20132837","journal-title":"Cancer Res"},{"key":"1059_CR18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(17)45142-1","volume":"136","author":"Haaff","year":"1986","unstructured":"Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970\u2013974","journal-title":"J Urol"},{"key":"1059_CR19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-5347(17)37582-1","volume":"147","author":"Hawkyard","year":"2005","unstructured":"Hawkyard SJ, Jackson AM, James K et al. (2005) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147: 1399\u20131403","journal-title":"J Urol"},{"key":"1059_CR20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"Herr","year":"1995","unstructured":"Herr HW ,Schwalb DM, Zhang ZF et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404\u20131408","journal-title":"J Clin Oncol"},{"key":"1059_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","volume":"47","author":"Jackson","year":"1994","unstructured":"Jackson AM, Alexandroff AB, McIntyre M et al. (1994) Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 47: 309\u2013312","journal-title":"J Clin Pathol"},{"key":"1059_CR22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"Jackson","year":"1995","unstructured":"Jackson AM, Prescott S, Hawkyard SJ et al. (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99: 369\u2013375","journal-title":"Clin Exp Immunol"},{"key":"1059_CR23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0022-5347(01)63835-7","volume":"159","author":"Jackson","year":"1998","unstructured":"Jackson AM (1998) Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 159: 1054\u20131063","journal-title":"J Urol"},{"key":"1059_CR24","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","volume":"14","author":"Kaempfer","year":"1996","unstructured":"Kaempfer R (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14: 1778\u20131786","journal-title":"J Clin Oncol"},{"key":"1059_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey, JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85: 62\u201367","journal-title":"J Clin Invest"},{"key":"1059_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","volume":"134","author":"Kelley","year":"1985","unstructured":"Kelley DR, Haaff EO, Becich M et al. (1985) Intravesical bacillus Calmette-Gu\u00e9rin-therapy for superficial bladder cancer: Effect of bacillus Calmette-Gu\u00e9rin viability on treatment results. J Urol 134: 48\u201353","journal-title":"J Urol"},{"key":"1059_CR27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","volume":"135","author":"Lage","year":"1986","unstructured":"Lage JM, Bauer WC, Kelley DR et al. (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol 135: 916\u2013919","journal-title":"J Urol"},{"key":"1059_CR28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"325","author":"Lamm","year":"1991","unstructured":"Lamm DL ,Crawford ED, Blumenstein BA et al.(1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205\u20131209","journal-title":"N Engl J Med"},{"key":"1059_CR29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm","year":"2000","unstructured":"Lamm DL (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124\u20131129","journal-title":"J Urol"},{"key":"1059_CR30","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"Ludwig","year":"2004","unstructured":"Ludwig AT (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386\u20133390","journal-title":"Cancer Res"},{"key":"1059_CR31","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Luo","year":"1999","unstructured":"Luo Y, Chen X, Downs T et al. (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162: 2399\u20132405","journal-title":"J Immunol"},{"key":"1059_CR32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","volume":"123","author":"Luo","year":"2001","unstructured":"Luo Y, Chen X, Han R, O\u2019Donnell MA (2001) Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123: 264\u2013270","journal-title":"Clin Exp Immunol"},{"key":"1059_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","volume":"137","author":"Luo","year":"2004","unstructured":"Luo Y (2004) Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137: 24\u201334","journal-title":"Clin Exp Immunol"},{"key":"1059_CR34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/jb.178.5.1274-1282.1996","volume":"178","author":"Mahairas","year":"1996","unstructured":"Mahairas GG, Sabo PJ, Hickey MJ et al. (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274\u20131282","journal-title":"J Bacteriol"},{"key":"1059_CR35","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"Malmstrom","year":"1999","unstructured":"Malmstrom PU, Wijkstrom H, Lundholm C et al. (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124\u20131127","journal-title":"J Urol"},{"key":"1059_CR36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF01534428","volume":"39","author":"McAveney","year":"1994","unstructured":"McAveney KM, Gomella LG, Lattime EC (1994) Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 39: 401\u2013406","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR37","first-page":"61","volume":"50","author":"Mendez-Samperio","year":"1999","unstructured":"Mendez-Samperio P, Ayala-Verdin HE, Trejo-Echeverria A (1999) Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner. Scand J Immunol 50: 61\u201367","journal-title":"Scand J Immunol"},{"key":"1059_CR38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/1097-0142(19920115)69:2<537::AID-CNCR2820690242>3.0.CO;2-3","volume":"69","author":"Mizutani","year":"1992","unstructured":"Mizutani Y, Nio Y, Fukumoto M, Yoshida O (1992) Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69: 537\u2013545","journal-title":"Cancer"},{"key":"1059_CR39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors. J Urol 116: 180\u2013183","journal-title":"J Urol"},{"key":"1059_CR40","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","volume":"166","author":"Morales","year":"2001","unstructured":"Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166: 1633\u20131638","journal-title":"J Urol"},{"key":"1059_CR41","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","volume":"163","author":"O","year":"1999","unstructured":"O\u2019Donnell MA, Arnold J, de Boer EC et al. (1999) Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol 163: 4246\u20134252","journal-title":"J Immunol"},{"key":"1059_CR42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"O","year":"2004","unstructured":"O\u2019Donnell MA, Lilli K, Leopold C (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888\u2013893","journal-title":"J Urol"},{"key":"1059_CR43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0090-4295(98)00188-5","volume":"52","author":"Poppas","year":"1998","unstructured":"Poppas DP, Pavlovich CP, Folkman J et al. (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52: 268\u2013275","journal-title":"Urology"},{"key":"1059_CR44","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","volume":"144","author":"Prescott","year":"1990","unstructured":"Prescott S, James K, Hargreave TB et al. (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248\u20131251","journal-title":"J Urol"},{"key":"1059_CR45","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB et al. (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147: 1636\u20131642","journal-title":"J Urol"},{"key":"1059_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01517219","volume":"41","author":"Pryor","year":"1995","unstructured":"Pryor K, Stricker P, Russell P et al. (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon \u03b12b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41: 309\u2013316","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1995.155","volume":"71","author":"Pryor","year":"1995","unstructured":"Pryor K, Goddard J, Goldstein D et al. (1995) Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71: 801\u2013807","journal-title":"Br J Cancer"},{"key":"1059_CR48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0090-1229(86)90055-3","volume":"41","author":"Ratliff","year":"1986","unstructured":"Ratliff TL, Shapiro A, Catalona WJ (1986) Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol 41: 108\u2013115","journal-title":"Clin Immunol Immunopathol"},{"key":"1059_CR49","first-page":"1762","volume":"47","author":"Ratliff","year":"1987","unstructured":"Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47: 1762\u20131766","journal-title":"Cancer Res"},{"key":"1059_CR50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"Ratliff","year":"1987","unstructured":"Ratliff TL, Gillen DP, Catalona WJ (1987) Requirement of a thymus-dependant immune response for BCG- mediated antitumor activity. J Urol 137: 155\u2013158","journal-title":"J Urol"},{"key":"1059_CR51","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJJ et al. (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150: 1018\u20131023","journal-title":"J Urol"},{"key":"1059_CR52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","volume":"127","author":"Riemensberger","year":"2002","unstructured":"Riemensberger J, Bohle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127: 20\u201326","journal-title":"Clin Exp Immunol"},{"key":"1059_CR53","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0022-5347(05)65522-X","volume":"166","author":"Saint","year":"2001","unstructured":"Saint F, Irani J, Salomon L et al. (2001) T helper 1\/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166: 2142\u20132147","journal-title":"J Urol"},{"key":"1059_CR54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","volume":"107","author":"Saint","year":"2003","unstructured":"Saint F, Kurth N, Maille P et al. (2003) Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107: 434\u2013440","journal-title":"Int J Cancer"},{"key":"1059_CR55","first-page":"1611","volume":"43","author":"Shapiro","year":"1983","unstructured":"Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Gu\u00e9rin and its correlation with bacillus Calmette-Gu\u00e9rin viability and natural killer cell activity. Cancer Res 43: 1611\u20131615","journal-title":"Cancer Res"},{"key":"1059_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2249.1995.tb03599.x","volume":"100","author":"Shin","year":"1995","unstructured":"Shin JS, Park JH, Kim JD et al. (1995) Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin. Clin Exp Immunol 100: 26\u201331","journal-title":"Clin Exp Immunol"},{"key":"1059_CR57","first-page":"2918","volume":"37","author":"Soloway","year":"1977","unstructured":"Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37: 2918\u20132929","journal-title":"Cancer Res"},{"key":"1059_CR58","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1128\/IAI.71.8.4647-4656.2003","volume":"71","author":"Suttmann","year":"2003","unstructured":"Suttmann H, Lehan N, Bohle A, Brandau S (2003) Stimulation of Neutrophil Granulocytes with Mycobacterium bovis Bacillus Calmette-Guerin Induces Changes in Phenotype and Gene Expression and Inhibits Spontaneous Apoptosis. Infect Immun 71: 4647\u20134656","journal-title":"Infect Immun"},{"key":"1059_CR59","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","volume":"172","author":"Suttmann","year":"2004","unstructured":"Suttmann H (2004) Mechanisms of Bacillus Calmette-Gu\u00e9rin-mediated Natural Killer Cell activation. J Urol 172: 1490\u20131495","journal-title":"J Urol"},{"key":"1059_CR60","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964\u20131970","journal-title":"J Urol"},{"key":"1059_CR61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174: 86\u201391","journal-title":"J Urol"},{"key":"1059_CR62","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","volume":"158","author":"Thalmann","year":"1997","unstructured":"Thalmann GN, Dewald B, Baggiolini M, Studer UE (1997) Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158: 1340\u20131344","journal-title":"J Urol"},{"key":"1059_CR63","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"Thalmann","year":"2000","unstructured":"Thalmann GN (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164: 2129\u20132133","journal-title":"J Urol"},{"key":"1059_CR64","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01517042","volume":"37","author":"Thanhauser","year":"1993","unstructured":"Thanhauser A (1993) Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37: 105\u2013111","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01520291","volume":"40","author":"Thanhauser","year":"1995","unstructured":"Thanhauser A (1995) The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40: 103\u2013108","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","volume":"52","author":"Watanabe","year":"2003","unstructured":"Watanabe E (2003) Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52: 481\u2013486","journal-title":"Cancer Immunol Immunother"},{"key":"1059_CR67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","volume":"26","author":"Weiss","year":"2003","unstructured":"Weiss GR (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26: 343\u2013348","journal-title":"J Immunother"},{"key":"1059_CR68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","volume":"86","author":"Zhao","year":"2000","unstructured":"Zhao W, Schorey JS, Bong-Mastek M et al. (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83\u201388","journal-title":"Int J Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-006-1059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-006-1059-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-006-1059-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:10:37Z","timestamp":1683450637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-006-1059-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s00120-006-1059-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}